Seattle Genetics (SGEN) to Present Data on Multiple ADCETRIS Trials
Of 33 evaluable patients, 79 percent obtained a complete remission, including ten patients who achieved PET-N following treatment with ADCETRIS alone and 16 patients who achieved PET-N following the entire treatment program of ADCETRIS sequenced with augmented ICE. All 26 patients underwent ASCT. Of the seven patients who remained PET positive after receiving augmented ICE, one patient underwent an ASCT, five patients received radiation therapy followed by ASCT and one patient received additional chemotherapy.
Of the 33 evaluable patients, 32 received an ASCT.
The most common adverse events of any grade were rash (70 percent) and neuropathy (45 percent).
Enrollment is ongoing. For more information about this trial, visit www.clinicaltrials.gov. Of 22 patients evaluable for response, eight patients (36 percent) achieved an objective response, including six complete remissions and two partial remissions.
In AITL, five of 10 evaluable patients (50 percent) achieved an objective response, including four complete remissions and one partial remission.
In PTCL-NOS, three of 12 evaluable patients (25 percent) achieved an objective response, including two complete remissions and one partial remission.
Of 17 evaluable patients, 82 percent achieved a tumor reduction.
Of the 29 patients evaluable for safety, the most common treatment-emergent adverse events of any grade were fatigue (24 percent), fever (17 percent), chills (14 percent), decreased appetite (14 percent), peripheral sensory neuropathy (14 percent) and rash (14 percent).
The most common Grade 3 adverse event was neutropenia (three patients). Other Grade 3 or 4 events occurring in one patient each included chills, decreased appetite, rash, pulmonary edema, increased lipase, confusional state, dyspnea, hypotension, hypoxia, peripheral motor neuropathy and tumor lysis syndrome. Three patient deaths occurred, including one due to acute respiratory distress syndrome and two others that were disease related. Objective Responses in Relapsed B-cell Lymphomas with Single-agent Brentuximab Vedotin (Abstract #304): Poster session Thursday, June 20, 2013 from 8:30 AM â 6:30 PM CET
Progression-free Survival Analyses of Two Pivotal Phase 2 Studies of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large-cell Lymphoma (Poster #303): Poster session Friday, June 21, 2013 from 8:30 AM â 6:30 PM CET
Two-Year Follow Up of Patients with Relapsed/Refractory Hodgkin Treated with Brentuximab Vedotin Prior to Reduced Intensity Allogenic Hematopoietic Cell Transplantation (Abstract #140): Oral session on Saturday, June 22, 2013 at 8:40 AM CET